Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Arch Capital Group Ltd. Reports 2025 Fourth Quarter Results (Business Wire) +++ ARCH CAPITAL Aktie -5,08%

News zum Sektor Gesundheit aus Nordamerika

Zum Sektor Gesundheit gehören Unternehmen der Pharmaka- & Biotechnologiebranche, Produzenten von medizintechnischen Geräten, Gesundheitsdienste, Kliniken und Pflegeeinrichtungen.
 >Gesundheit ETFs & Fonds 
Es sind 102 ETFs & Fonds zum Sektor Gesundheit bekannt.
 >Aktien zum Sektor Gesundheit 
Es sind 1555 Aktien zum Sektor Gesundheit bekannt.
 
10.02.26 - 03:24
Why Elevra Lithium, Pro Medicus, Sims, and Treasury Wine shares are roaring higher (Fool)
 
These shares are having a better day than most on Tuesday. The post Why Elevra Lithium, Pro Medicus, Sims, and Treasury Wine shares are roaring higher appeared first on The Motley Fool Australia....
10.02.26 - 02:30
2 Intriguing Medical Stocks to Watch as Q4 Results Approach: EXEL, GILD (Zacks)
 
With their Q4 results approaching after-market hours on Tuesday, February 10, Exelixis (EXEL) and Gilead Sciences (GILD) are two top-performing medical stocks to consider....
10.02.26 - 01:00
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
 
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of +21.50% and +19.52%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?...
10.02.26 - 01:00
Medpace (MEDP) Beats Q4 Earnings and Revenue Estimates (Zacks)
 
Medpace (MEDP) delivered earnings and revenue surprises of +11.79% and +4.01%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?...
10.02.26 - 01:00
DLH Holdings Corp. (DLHC) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
 
DLH (DLHC) delivered earnings and revenue surprises of -28.57% and -1.79%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?...
10.02.26 - 01:00
Moderna (MRNA) Laps the Stock Market: Here′s Why (Zacks)
 
In the latest trading session, Moderna (MRNA) closed at $41.95, marking a +2.29% move from the previous day....
10.02.26 - 01:00
Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts (Zacks)
 
In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $19.33, denoting a -16.05% move from the preceding trading day....
10.02.26 - 00:12
Moody′s bestätigt B3-Rating für Fortrea und hebt Ausblick auf "stabil" an (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
10.02.26 - 00:00
Stock Market Today, Feb. 9: Hims & Hers Health Drops 16% on Novo Nordisk Lawsuit (Fool)
 
Today, Feb. 9, 2026, investors are reevaluating Hims & Hers after it pulled its weight-loss pill, facing legal action and FDA scrutiny....
09.02.26 - 23:39
Edwards Lifesciences Q4 2025 Earnings Preview (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
09.02.26 - 23:33
Invasive Fungal Infections Market to Witness Upsurge in Growth at a CAGR of 11.4% (in the US) During the Forecast Period (2025-2034) | DelveInsight (PR Newswire)
 
The invasive fungal infections market is expected to grow by 2034, owing to the approval of new agents such as Ibrexafungerp (Glaxosmithkline/SCYNEXIS), Fosmanogepix (Basilea Pharmaceutica), Olorofim (F901318) (Shionogi/F2G), Opelconazole (PC945) (Pulmocide), and others in frontline and......
09.02.26 - 23:18
Novo Says It′s Suing Hims to Halt Obesity Drug Copycats  (Bloomberg)
 
Bloomberg News Health Reporter Madison Muller reports on the latest on Novo's lawsuit. - Novo Nordisk said it's suing Hims & Hers Health Inc. for making knock-offs of its obesity medicines, even as Hims scrapped plans to sell a copycat version of the Wegovy pill. Hims is breaching the US patent on semaglutide, the active ingredient in Novo's blockbuster obesity treatments, Novo argued Monday. The US lawsuit attacks not only Hims' new strategy to launch a copycat pill but also goes after shots that mimic Wegovy and its sister drug Ozempic. The move marks a more aggressive approach for Novo under Chief Executive Officer Mike Doustdar. Until now, the drugmaker's legal strategy focused on the way that companies like Hims market their products. Novo said this is the first time it has sued over patent infringement for compounded semaglutide. (Source: Bloomberg)...
09.02.26 - 23:09
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, February 25, 2026 (Business Wire)
 
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its fourth quarter and full year 2025 financial and operating results after the market close on Wednesday, February 25, 2026, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial 1-800-343-4136 or 1-203-518-9843 and reference Maravai LifeSciences, Conference ID: MARAVAI. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at https://investors.maravai.com. About Maravai Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai's companies are leaders in providing products and services in the fields of nucleic acid synthesis ...
09.02.26 - 23:03
Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters′ Option to Purchase Additional Shares (Business Wire)
 
TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it has completed its previously-announced underwritten public offering (the “Offering”) of 5,168,019 common shares, which includes the exercise of the underwriters' option to purchase an additional 712,574 common shares and, in lieu of common shares for certain investors, pre-funded warrants to purchase 495,049 common shares. The common shares were sold at a price of US$10.10 per share (C$13.81 per common share) and the pre-funded warrants were sold at a price of US$10.09999 per pre-funded warrant (C$13.80999 per pre-funded warrant), which represents the per share price for the common shares less the C$0.00001 per share exercise price for each pre-funded warrant. The total gross proceeds to the Company were approximately US$57.2 million, before deducting...
09.02.26 - 22:48
FDA-Rückschlag für REGENXBIO: Aktie bricht nach Ablehnung von Gentherapie ein (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
09.02.26 - 22:36
Hims & Hers Collapses After FDA Vows to Restrict Copycat GLP-1 Pill. Is the Stock Toast? (Fool)
 
Hims & Hers could face difficulty in the future in selling copycat GLP-1 drugs....
09.02.26 - 22:30
FDA Denies Regenxbio Gene Therapy in Latest Rare Disease Setback (Bloomberg)
 
US regulators rejected a gene therapy from Regenxbio Inc. to treat a rare disease that causes brain damage in boys, the latest sign that the Trump administration is taking a hard line on drug approvals for uncommon conditions....
09.02.26 - 22:24
Medpace GAAP EPS of $4.67 beats by $0.48, revenue of $708.5M beats by $17.57M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
09.02.26 - 22:21
Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Results (Business Wire)
 
Revenue of $708.5 million in the fourth quarter of 2025 increased 32.0% from revenue of $536.6 million for the comparable prior-year period, representing a backlog conversion rate of 23.6%. Net new business awards were $736.6 million in the fourth quarter of 2025, representing an increase of 39.1% from net new business awards of $529.7 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.04x. Fourth quarter of 2025 GAAP net income was $135.1 million, or $4.67 per diluted share, versus GAAP net income of $117.0 million, or $3.67 per diluted share, for the comparable prior-year period. Net income margin was 19.1% and 21.8% for the fourth quarter of 2025 and 2024, respectively. EBITDA was $160.2 million for the fourth quarter of 2025, an increase of 20.0% from EBITDA of $133.5 million for the comparable prior-year period, resulting in an EBITDA margin of 22.6%. CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Das Gegenwärtige ist begrenzt. Das Mögliche ist unermeßlich. - Abraham Lincoln
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!